| Japanese |
|---|
| Title | テクネシウム早期摂取率によるバセドウ病の寛解予測 |
|---|
| Subtitle | ≪原著≫ |
|---|
| Authors | 御前隆*, 土光茂治*, 黄俊清**, 新保慎一郎**, 日高昭斉***, 飯田泰啓***, 笠木寛治***, 小西淳二*** |
|---|
| Authors(kana) | |
|---|
| Organization | *京都市立病院放射線科, **内分泌科, ***京都大学核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 28 |
|---|
| Number | 2 |
|---|
| Page | 157-161 |
|---|
| Year/Month | 1991/2 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」バセドウ病を抗甲状腺剤で治療する際, 投薬中止時期を決める指標としてはいろいろな方法が提唱されているがまだ決め手となるものはない. 今回は従来のT3抑制試験の前値に相当する, 1回のテクネシウム早期摂取率のみで服薬中止後の予後の予測を試みた. 抗甲状腺剤に反応して維持量で甲状腺機能が正常に保たれているバセドウ病患者のうち, 30分摂取率が4.0%以下となった75例で投薬を中止し, 毎月経過を観察した. 1年後に評価可能であった64例のうち55例(約86%)は機能正常を保ち, 8例に再発, 1例に機能低下がみられた. この方法は簡便・迅速であり, しかも精度は従来の各種の試験に勝るとも劣らないものであった. 今後実際臨床の場で用いるのに適していると考えられる. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Graves' disease, Technetium pertechnetate, Thyroid uptake, Antithyroid drugs. |
|---|
| English |
|---|
| Title | Prediction of Remission in Graves' Disease after Thionamide Therapy by Technetium-99m Early Uptake |
|---|
| Subtitle | - Original Articles - |
|---|
| Authors | Takashi MISAKI*, Shigeharu DOKOH*, Toshikiyo KOH**, Shin-ichiro SHIMBO**, Akinari HIDAKA***, Yasuhiro IIDA***, Kanji KASAGI***, Junji KONISHI*** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology, **Internal Medicine, Kyoto City Hospital, ***Department of Nuclear Medicine, Kyoto University School of Medicine |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 28 |
|---|
| Number | 2 |
|---|
| Page | 157-161 |
|---|
| Year/Month | 1991/2 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] In the clinical management of Graves' thyrotoxicosis, one of the most important subject is when to stop antithyroid drugs after achieving an euthyroid state. T3 suppression test and other methods have been used to forecast the outcome after drug cessation, but the results were not always satisfactory. We have attempted to predict remission of Graves' disease by single measurement of early technetium uptake without administration of triiodothyronine. Drugs were discontinued in the seventy-five patients with Graves' disease on maintenance doses of either methimazole or propylthiouracil who showed normalized uptake (4.0% or less). Of 64 patients evaluable after twelve months, 55 (86%) remained euthyroid, 8 relapsed, and 1 became hypothyroid. With its accuracy in prediction of short-term remission comparable or superior to T3 suppression test, this rapid and simple method seemed suitable for routine use in clinical practice. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Graves' disease, Technetium pertechnetate, Thyroid uptake, Antithyroid drugs. |
|---|